β-1,3-Gal-T5 Inhibitors
Chemical inhibitors of β-1,3-Gal-T5 can affect the enzyme's activity through various biochemical mechanisms. CAST, by inhibiting calpain, can lead to a decrease in β-1,3-Gal-T5 activity, as calpain is necessary for the proper folding and functioning of many proteins, including glycosyltransferases. Therefore, CAST's action can result in β-1,3-Gal-T5 misfolding, which in turn hampers its enzymatic activity. Similarly, PD173074, as an FGFR tyrosine kinase inhibitor, can alter the signaling pathways that regulate the expression and activity of β-1,3-Gal-T5. This disruption can decrease the functional activity of β-1,3-Gal-T5 by changing the cellular environment it depends on for its expression and activity.
Swainsonine and kifunensine inhibit different mannosidase enzymes, which play critical roles in glycoprotein biosynthesis. By inhibiting these enzymes, the inhibitors can reduce the substrate availability for β-1,3-Gal-T5, effectively decreasing its functional activity due to a lack of properly processed glycoproteins. Brefeldin A, Monensin, and tunicamycin disrupt various aspects of the cellular machinery involved in the trafficking and processing of glycoproteins. Brefeldin A inhibits ADP-ribosylation factor, Monensin disrupts Golgi function, and tunicamycin blocks N-linked glycosylation. These disruptions can prevent β-1,3-Gal-T5 from reaching its site of action or from accessing the substrates necessary for its activity. Deoxynojirimycin and its analogs, including deoxymannojirimycin and NB-DNJ, inhibit different glucosidases. These inhibitors can interfere with the folding and quality control of glycoproteins, which may indirectly inhibit the function of β-1,3-Gal-T5 by affecting the pool of correctly folded glycoproteins available for further processing. Lastly, Compound C and cerulenin can indirectly inhibit β-1,3-Gal-T5 by altering cellular metabolism and membrane lipid composition, respectively. Compound C inhibits AMPK, potentially affecting the energy status and glycosylation capacity of the cell, while cerulenin inhibits fatty acid synthase, which could change the lipid environment of the Golgi apparatus where β-1,3-Gal-T5 operates.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an FGFR tyrosine kinase inhibitor. Given that glycosyltransferases like β-1,3-Gal-T5 rely on proper signaling for their expression and activity, inhibition of FGFR could lead to a decrease in β-1,3-Gal-T5 activity due to altered cellular signaling. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an inhibitor of alpha-mannosidase II, an enzyme involved in glycoprotein biosynthesis. By inhibiting upstream steps in glycoprotein processing, swainsonine could reduce the substrate availability for β-1,3-Gal-T5, thereby functionally inhibiting its activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which is involved in the regulation of vesicle trafficking in cells. Disruption of vesicle trafficking can inhibit the transport of glycosyltransferases like β-1,3-Gal-T5 to their site of action, thus inhibiting its function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts Golgi function, where β-1,3-Gal-T5 is localized and active. By disrupting the Golgi apparatus, Monensin can inhibit the processing and function of β-1,3-Gal-T5 by preventing its proper localization within the cell. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the first step in the synthesis of the lipid-linked oligosaccharide precursor. This leads to a reduction in glycoprotein synthesis, which could inhibit the function of glycosyltransferases such as β-1,3-Gal-T5 by limiting substrate availability. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase inhibitor which can lead to the accumulation of misfolded glycoproteins. This can inhibit the function of β-1,3-Gal-T5 by impairing the folding and maturation of proteins that might be substrates or regulators of this enzyme. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin is an inhibitor of glucosidases. By inhibiting these enzymes, it can interfere with the proper folding and quality control of glycoproteins, which may indirectly inhibit the function of glycosyltransferases like β-1,3-Gal-T5 by affecting the pool of correctly folded glycoproteins. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin is an inhibitor of mannosidase, which could lead to improper protein glycosylation. This misprocessing can hamper the function of β-1,3-Gal-T5 by affecting the synthesis or availability of its glycoprotein substrates. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Compound C is an inhibitor of AMP-activated protein kinase (AMPK). Since AMPK can regulate cellular metabolism, which affects glycosylation processes, inhibiting AMPK with Compound C could indirectly inhibit the function of β-1,3-Gal-T5 by altering the energy status of the cell and glycosylation capacity. | ||||||